NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. reported a net loss of $22.1 million for FY 2025, or -$4 basic loss per share attributable to common stockholders, compared to prior periods with ongoing losses amid business realignment. Continuing operations drove a $33.2 million net loss, primarily from $24.5 million non-cash loss on warrant liability changes and $8.4 million operating loss due to $7.6 million general and administrative expenses plus $854K impairment. Discontinued operations contributed $11.1 million net income, offsetting some losses. Balance sheet shows $9.0 million total assets, including $8.0 million cash, against $31.9 million liabilities and -$23.2 million stockholders' deficit, reflecting warrant liabilities of $30.4M. Cash flow from continuing operations used $8.4 million in operations, partially offset by $4.6 million financing inflows, netting -$3.8 million decrease. The company divested legacy eyecare and wound care assets, shifting to a digital asset strategy focused on SKY tokens post-January 2026 private placement. Liquidity supports operations through March 2027, with emphasis on capital allocation to revenue-generating digital assets amid regulatory and volatility risks.

Key Takeaways